AstraZeneca Stock Slides Despite Positive Tezspire Trial Results

AstraZeneca's stock price declined by nearly 2% in pre-market hours despite positive results from a late-stage clinical trial of its Tezspire drug.

The trial, which was conducted for treating eosinophilic esophagitis, showed that Tezspire successfully achieved both primary and secondary objectives, reducing inflammation and improving swallowing ability in patients compared to those receiving a placebo.

Eosinophilic esophagitis is a chronic inflammatory disorder affecting over 470,000 individuals in the United States, causing significant eating challenges and anxiety. The condition creates difficulties with food movement through the esophagus or lodging of food.

Tezspire's therapeutic mechanism involves inhibiting TSLP, a protein that triggers inflammation associated with eosinophils, specialized white blood cells. This approach is identical to its approved application for severe asthma treatment and has generated $1.13 billion in revenue for AstraZeneca throughout 2025.

Despite the promising trial results, analysts maintain a Strong Buy rating on AZN, with a mean price target of $221.40, suggesting approximately 33% potential upside from present trading levels.